ClinicalTrials.gg
Active, not recruitingNCT05314023Updated Jan 19, 2023

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

A Phase 3 interventional study of 9vHPV vaccine in Genital Warts, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 5 sites in China. Open to male participants aged 9 Years to 19 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,590
Allocation
Non-randomized
Ages
9 Years to 19 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata — 2 open to participants now, 4 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Condylomata Acuminata.

Planned enrollment
4th of 10
1,590 · median 1,206
Started
2022
the only one that year
Phase 3
9 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
6 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, this one is the 4th largest by planned enrollment, is the only one that started in 2022, is one of 9 in phase 3, and was the 8th registered.

Condylomata Acuminata

116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.

Browse Condylomata Acuminata studies →

Open to participants now

2 of the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Condylomata Acuminata studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 9 Years to 19 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, or all of them as a file.
02

Study summary

This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in Chinese males 9 through 14 years of age, compared to the 3 dose regimen in Chinese males 20 through 26 years of age (from Merck Protocol V503-052). The primary hypothesis is that each of the 3-dose regimen in Chinese males aged 9 through 19 years and 2-dose regimens in Chinese males aged 9 through 14 years induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) at one month post last dose compared to the 3-dose regimen in Chinese adult males aged 20 through 26 years. A noninferiority margin of 0.67 in the GMT ratio (9 through 19 years of age or 9 through 14 years of age vs 20 through 26 years of age) is used for each HPV type.

03

Conditions studied

  • Genital Warts

Browse trials for

04

Who can participate

Ages eligible
9 Years to 19 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a healthy Chinese male.
  • Has not had sexual debut at the time of enrollment, and does not plan on becoming sexually active during the vaccination period (Day 1 through one month post last dose).

Exclusion criteria

Exclusion Criteria:

  • Has a history of known prior vaccination with an HPV vaccine.
  • Has a history of HPV-related external genital lesions, HPV-related intra-anal lesions, or HPV-related head and neck cancer.
  • Has a history of severe allergic reaction that required medical intervention.
  • Has received immune globulin or blood-derived products in the past 6 months or plans to receive any before one month post last dose.
  • Has a history of splenectomy, is currently , or has been diagnosed with immunodeficiency, (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other condition.
  • Has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical and certain regimens of systemic corticosteroids.
  • Has a known thrombocytopenia or coagulation disorder that would contraindicate IM injections.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,590 participants (estimated)

Study arms

  • Experimental
    9 to 19 Years Old: Day 1, Months 2 and 6

    Chinese males 9 to 19 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6

    Biological: 9vHPV vaccine

  • Experimental
    9 to 14 Years Old: Day 1, and Month 6

    Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 6

    Biological: 9vHPV vaccine

  • Experimental
    9 to 14 Years Old: Day 1 and Month 12

    Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 12

    Biological: 9vHPV vaccine

Interventions

  • Biological9vHPV vaccine

    A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

    Also known as: V503, GARDASIL™9

06

What researchers measure

Primary outcomes

  1. Competitive Luminex immunoassay (cLIA) GMTs to 9 vaccine types of 9vHPV vaccine at one month post last dose

    cLIA GMT to each of 9 vaccine types of 9vHPV vaccine at one month post last dose. The GMT for each HPV type will be reported in mMU/mL.

    Time frame: Up to Month 13

  2. cLIA GMTs to 9 vaccine types of 9vHPV vaccine up to 60 months post last dose

    cLIA GMT to each of 9 vaccine types of 9vHPV vaccine at up to 60 months post last dose. The GMT for each HPV type will be reported in mMU/mL.

    Time frame: Up to 72 months

  3. cLIA seropositivity percentages to 9 vaccine types of 9vHPV vaccine

    cLIA seropositivity to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized.

    Time frame: Up to 72 months

Secondary outcomes

  1. cLIA seroconversion percentages to 9 vaccine types of 9vHPV vaccine

    cLIA seroconversion to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized.

    Time frame: Up to Month 13

  2. Immunoglobulin G Luminex immunoassay (IgG LIA) GMTs to 9 vaccine types of 9vHPV vaccine at one month post last dose

    IgG LIA GMT to each of 9 vaccine types of 9vHPV vaccine at one month post last dose. The GMT for each HPV type will be reported in mMU/mL.

    Time frame: Up to Month 13

  3. IgG LIA seroconversion percentages to 9 vaccine types of 9vHPV vaccine

    IgG LIA seroconversion to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized.

    Time frame: Up to Month 13

  4. Percentage of participants experiencing solicited injection-site adverse events (AEs),

    An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Solicited injection-site AEs such as erythema, swelling, pain, and induration at the injection site will be recorded.

    Time frame: Day 1 through Day 8 following any study vaccination

  5. Percentage of participants experiencing solicited systemic AEs

    An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Systemic AEs are those not categorized as injection-site AEs.

    Time frame: Day 1 through Day 8 following any study vaccination

  6. Percentage of participants experiencing serious AEs (SAEs)

    A SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event.

    Time frame: Up to 72 months

  7. IgG LIA GMTs to 9 vaccine types of 9vHPV vaccine up to 60 months post last dose

    IgG LIA GMT to each of 9 vaccine types of 9vHPV vaccine up to 60 months post last dose. The GMT for each HPV type will be reported in mMU/mL.

    Time frame: Up to 72 months

  8. IgG LIA seropositivity percentages to 9 vaccine types of 9vHPV vaccine

    IgG LIA seropositivity to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized.

    Time frame: Up to 72 months

07

Study locations

5 sites
  • Liucheng County Centers for Disease Control and Prevention ( Site 0005)
    Liuzhou, Guangxi 545200, China
  • Center for Disease Control and Prevention of Rong An ( Site 0006)
    Liuzhou, Guangxi 545400, China
  • Loudi Public Health Hospital (Loudi Occupational Disease Prevention And Treatment Hospital) ( Site 0
    Louxing District, Hunan 417000, China
  • Yuechi Disease Prevention and Control Center ( Site 0002)
    Guang'an, Sichuan 638399, China
  • Santai County Center for Disease Control and Prevention ( Site 0001)
    Mianyang, Sichuan 621100, China
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Feb 2029, 81 months after the start.

Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Apr 6, 2022
StartActual
May 7, 2022
Primary completionEst.
Feb 19, 2029
CompletionEst.
Feb 19, 2029
Last update
Jan 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05314023
Responsible party
Sponsor
First posted
Apr 6, 2022
Start date
May 7, 2022
Primary completion
Feb 19, 2029 (estimated)
Completion
Feb 19, 2029 (estimated)
Last update
Jan 19, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion